MRI guided prostate biopsy best way of active surveillance for prostate cancer
Prostate cancer is a common type of male cancer which is highly treatable in the early stages. All over the world tens of thousands of men are diagnosed with low-risk prostate cancer. All such patients are asked just to monitor their slow-growing tumours as they need no active treatment.
Magnetic resonance imaging-guided prostate biopsy best way of active surveillance for prostate cancer, find researcher. MRI imaging, let doctors see the majority of prostate tumours and take a biopsy from the exact location of cancer within the prostate.
Doctors relied on ultrasound to guide a biopsy needle into the prostate in the past. However, ultrasound doesn't allow the visualisation of prostate tumours, so a biopsy may have missed a tumour. Over the past decade, it's become possible to instead perform a MRI guided biopsy.
Prostate cancer is typically detected with a blood test measuring levels of prostate-specific antigen (PSA). However, elevated PSA levels detect not only aggressive prostate tumours, but also very slow-growing cancers that are unlikely to become life-threatening. Men with higher than usual PSA levels are referred to get a biopsy, in which cells are collected from the prostate reveal more details about a tumour.
We've found that when you use an MRI-guided biopsy to confirm what appears to be a low-risk prostate cancer, you can then tell the patient with pretty good accuracy what the future is going to entail and what his risks are of having a cancer that will require treatment in the future, said the senior author of the study.
If you know exactly where to put the biopsy needle, you've a much better chance of getting answers about a tumour, said a researcher. Earlier this year, his group reported that combining MRI-guided biopsies with a more traditional approach of sampling throughout the prostate detects more cancers than either approach alone. However, he said questions have lingered about the clinical benefit of MRI imaging guided biopsies and exactly when they should be used in the monitoring process.
From 2009-2018, 606 men with prostate cancers of apparent low risk were enrolled in the active surveillance program. For the new study, researchers analysed data on 332 of those men, all of whom received an initial MRI-guided biopsy and at least one follow-up biopsy an average of 3.9 years later.
The researchers found that when a man's prostate tumour had a Gleason Score of 7 at the time of an MRI-guided biopsy, there was a three-and-a-half times greater risk that the man would develop higher-risk cancer compared to men who had a negative biopsy. ( The Gleason Score is a grading system used to determine the aggressiveness of prostate cancer). A score of 6 is generally considered low-risk cancer recommended for active surveillance, while a score of 7 or more may require radiation or surgery.
Moreover, combining an MRI-guided biopsy with the more standard approach of taking a systematic sampling of biopsies from around the prostate boosted the likelihood that a positive initial biopsy result was truly positive.
In the study, the risk of later developing high-grade prostate cancer was less than 8% for men whose biopsies were negative, 11% if the biopsy revealed a Gleason Score of 6, and 23% with a score of 7.
While MRI-guided biopsy is being used, it is still not being very widely used and our results have the potential to establish a new standard for using it in active surveillance, said the researcher.
MRI-guided biopsy can be used to determine which men should receive more frequent follow-up biopsies or even active intervention before a higher-grade tumour develops, he said.
The study also integrated the use of tracked biopsies- in which technology lets physician take a follow-up biopsy from the same location as a previous biopsy to determine how cancer is changing. The team found that the tracked biopsy detected more upward changes in the grading of cancer-- from a low-grade to high-grade tumour-- than non-tracked biopsies. However, more work is needed to study the value of tracked biopsies.
All these new technologies are advancing the field and serving patients better, he said.
this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.
https://gscrochetdesigns.blogspot.com. one can see my crochet creations
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
Magnetic resonance imaging-guided prostate biopsy best way of active surveillance for prostate cancer, find researcher. MRI imaging, let doctors see the majority of prostate tumours and take a biopsy from the exact location of cancer within the prostate.
Doctors relied on ultrasound to guide a biopsy needle into the prostate in the past. However, ultrasound doesn't allow the visualisation of prostate tumours, so a biopsy may have missed a tumour. Over the past decade, it's become possible to instead perform a MRI guided biopsy.
Prostate cancer is typically detected with a blood test measuring levels of prostate-specific antigen (PSA). However, elevated PSA levels detect not only aggressive prostate tumours, but also very slow-growing cancers that are unlikely to become life-threatening. Men with higher than usual PSA levels are referred to get a biopsy, in which cells are collected from the prostate reveal more details about a tumour.
We've found that when you use an MRI-guided biopsy to confirm what appears to be a low-risk prostate cancer, you can then tell the patient with pretty good accuracy what the future is going to entail and what his risks are of having a cancer that will require treatment in the future, said the senior author of the study.
If you know exactly where to put the biopsy needle, you've a much better chance of getting answers about a tumour, said a researcher. Earlier this year, his group reported that combining MRI-guided biopsies with a more traditional approach of sampling throughout the prostate detects more cancers than either approach alone. However, he said questions have lingered about the clinical benefit of MRI imaging guided biopsies and exactly when they should be used in the monitoring process.
From 2009-2018, 606 men with prostate cancers of apparent low risk were enrolled in the active surveillance program. For the new study, researchers analysed data on 332 of those men, all of whom received an initial MRI-guided biopsy and at least one follow-up biopsy an average of 3.9 years later.
The researchers found that when a man's prostate tumour had a Gleason Score of 7 at the time of an MRI-guided biopsy, there was a three-and-a-half times greater risk that the man would develop higher-risk cancer compared to men who had a negative biopsy. ( The Gleason Score is a grading system used to determine the aggressiveness of prostate cancer). A score of 6 is generally considered low-risk cancer recommended for active surveillance, while a score of 7 or more may require radiation or surgery.
Moreover, combining an MRI-guided biopsy with the more standard approach of taking a systematic sampling of biopsies from around the prostate boosted the likelihood that a positive initial biopsy result was truly positive.
In the study, the risk of later developing high-grade prostate cancer was less than 8% for men whose biopsies were negative, 11% if the biopsy revealed a Gleason Score of 6, and 23% with a score of 7.
While MRI-guided biopsy is being used, it is still not being very widely used and our results have the potential to establish a new standard for using it in active surveillance, said the researcher.
MRI-guided biopsy can be used to determine which men should receive more frequent follow-up biopsies or even active intervention before a higher-grade tumour develops, he said.
The study also integrated the use of tracked biopsies- in which technology lets physician take a follow-up biopsy from the same location as a previous biopsy to determine how cancer is changing. The team found that the tracked biopsy detected more upward changes in the grading of cancer-- from a low-grade to high-grade tumour-- than non-tracked biopsies. However, more work is needed to study the value of tracked biopsies.
All these new technologies are advancing the field and serving patients better, he said.
this is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.
https://gscrochetdesigns.blogspot.com. one can see my crochet creations
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
Labels: (PSA) prostate-specific antigen, active surveillance, aggressiveness of, determines, Gleason Score, grading system, low-grade. high grade tumour, MRI-guided prostate biopsy, prostate cancers
posted by G S Iyer at 8:26 AM
0 Comments:
Post a Comment
<< Home